Get Clarity, Not Just Headlines.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Zohran Mamdani
NATO
New York State Politics
Artificial Intelligence
Social Media
Donald Trump
Heatwaves
NBA
Education
Amazon
War
Regulation
Published • loading... • Updated

Alzheimer’s R&D resurgence driven by acquisitions in 2025YTD

Summary by Pharmaceutical-technology.com
Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 billion in 2024.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
pharmaceutical-technology.compharmaceutical-technology.com

Alzheimer’s R&D resurgence driven by acquisitions in 2025YTD

Acquisitions involving innovator drugs have grown year-on-year with total deal value increasing eight-fold to almost $18 billion in 2024.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmaceutical-technology.com broke the news in on Wednesday, June 25, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

News
For You
SearchBlindspotLocal